THE THROMBOXANE RECEPTOR ANTAGONIST SQ-30,741 REDUCES MYOCARDIAL INFARCT SIZE IN MONKEYS WHEN GIVEN DURING REPERFUSION AT A THRESHOLD DOSE FOR IMPROVING REFLOW DURING THROMBOLYSIS

被引:16
作者
SCHUMACHER, WA
GROVER, GJ
机构
[1] Department of Pharmacology, The Squibb Institute for Medical Research, Princeton, NJ
关键词
D O I
10.1016/0735-1097(90)90288-Z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The threshold dose of the selective thromboxane receptor antagonist SQ 30,741 for increasing reflow during thrombolysis was identified and then evaluated in a model of myocardial ischemia with reperfusion. In anesthetized cynomolgus monkeys, stenotic carotid arteries were occluded with a platelet-rich thrombus by electrical stimulation and recanalized with streptokinase (680 U/min intraarterially for 1 h) and heparin (200 U/kg + 120 U/h intravenously for 3 h). Concurrent administration of SQ 30,741 (2.1 mg/kg + 0.5 mg/kg per h intravenously for 3 h; n = 4) enhanced the extent of reflow 174% compared with saline solution (n = 4; p < 0.05) during the third hour, when lower doses were ineffective. This threshold dose was tested in anesthetized African green monkeys subjected to 90 min of left circumflex coronary artery occlusion and 5 h of reperfusion. SQ 30,741 (n = 8) or saline solution (n = 11) was administered 2 min before reperfusion and continued throughout reperfusion. The heart was removed on termination of reperfusion and perfused in vitro with Evans blue and triphenyltetrazolium chloride dyes to stain tissue at risk and infarcted tissue, respectively. The percent of left ventricle at risk did not differ between saline- (37 ± 4%) and SQ 30,741-treated (35 ± 3%) monkeys. In contrast, infarcted tissue expressed as percent of the left ventricle at risk was less (p < 0.01) in monkeys receiving SQ 30,741 (31 ± 2%) than in those receiving saline solution (49 ± 5%). This 36% reduction in infarct size occurred without significant differences between treatments in hemodynamic variables and myocardial blood flows (as assessed by radioactive microspheres) measured during control, occlusion and reperfusion intervals. Thus, a dose of SQ 30,741 that stabilizes reflow after thrombolysis also possesses antiischemic activity when administered only during coronary reperfusion in monkeys. © 1990.
引用
收藏
页码:883 / 889
页数:7
相关论文
共 26 条
[1]   PROTECTIVE EFFECT OF THE SPECIFIC THROMBOXANE RECEPTOR ANTAGONIST, BM-13505, IN REPERFUSION INJURY FOLLOWING ACUTE MYOCARDIAL ISCHEMIA IN CATS [J].
BHAT, AM ;
SACKS, H ;
OSBORNE, JA ;
LEFER, AM .
AMERICAN HEART JOURNAL, 1989, 117 (04) :799-803
[2]   THROMBOXANE INDUCED RED-BLOOD-CELL LYSIS [J].
BREZINSKI, ME ;
LEFER, DJ ;
BOWKER, B ;
LEFER, AM .
PROSTAGLANDINS, 1987, 33 (01) :75-84
[3]   RESPONSIVENESS OF PLATELETS AND CORONARY-ARTERIES FROM DIFFERENT SPECIES TO SYNTHETIC THROMBOXANE AND PROSTAGLANDIN ENDOPEROXIDE ANALOGS [J].
BURKE, SE ;
LEFER, AM ;
NICOLAOU, KC ;
SMITH, GM ;
SMITH, JB .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 78 (02) :287-292
[4]  
CROSS PE, 1987, ANNU REP MED CHEM, V22, P95
[5]   RELATIVE ERROR AND VARIABILITY IN BLOOD-FLOW MEASUREMENTS WITH RADIOLABELED MICROSPHERES [J].
DOLE, WP ;
JACKSON, DL ;
ROSENBLATT, JI ;
THOMPSON, WL .
AMERICAN JOURNAL OF PHYSIOLOGY, 1982, 243 (03) :H371-H378
[6]   EARLY PHASE ACUTE MYOCARDIAL INFARCT SIZE QUANTIFICATION - VALIDATION OF THE TRIPHENYL TETRAZOLIUM CHLORIDE TISSUE ENZYME STAINING TECHNIQUE [J].
FISHBEIN, MC ;
MEERBAUM, S ;
RIT, J ;
LANDO, U ;
KANMATSUSE, K ;
MERCIER, JC ;
CORDAY, E ;
GANZ, W .
AMERICAN HEART JOURNAL, 1981, 101 (05) :593-600
[7]   MARKED PLATELET ACTIVATION INVIVO AFTER INTRAVENOUS STREPTOKINASE IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION [J].
FITZGERALD, DJ ;
CATELLA, F ;
ROY, L ;
FITZGERALD, GA .
CIRCULATION, 1988, 77 (01) :142-150
[8]   SIMULTANEOUS ADMINISTRATION OF THROMBOXANE-A2-RECEPTOR AND SEROTONIN-S2-RECEPTOR ANTAGONISTS MARKEDLY ENHANCES THROMBOLYSIS AND PREVENTS OR DELAYS REOCCLUSION AFTER TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN A CANINE MODEL OF CORONARY-THROMBOSIS [J].
GOLINO, P ;
ASHTON, JH ;
MCNATT, J ;
GLASGREENWALT, P ;
SHENGKUN, Y ;
OBRIEN, RA ;
BUJA, LM ;
WILLERSON, JT .
CIRCULATION, 1989, 79 (04) :911-919
[9]   THE EFFECT OF THE THROMBOXANE A2 PROSTAGLANDIN ENDOPEROXIDE RECEPTOR ANTAGONIST SQ 30,741 ON MYOCARDIAL INFARCT SIZE AND BLOOD-FLOW DURING MYOCARDIAL ISCHEMIA AND REPERFUSION [J].
GROVER, GJ ;
SCHUMACHER, WA ;
SIMON, M ;
PARHAM, C .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 12 (06) :701-709
[10]  
GROVER GJ, 1989, J PHARMACOL EXP THER, V248, P484